Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Group 1 - Neurocrine is focusing on developing and commercializing drugs for neuropsychiatric conditions, with a strategic shift in R&D approach [1][2] - The company has an upcoming R&D Day on December 16, where further details on the evolution of its strategy will be shared [1] - The current pipeline has been largely in-licensed through business development, which will continue to be a significant part of Neurocrine's strategy [2]